Literature DB >> 16409454

Indicators of lifetime endogenous estrogen exposure and risk of venous thromboembolism.

T Simon1, M Beau Yon de Jonage-Canonico, E Oger, D Wahl, J Conard, G Meyer, J Emmerich, M-T Barrellier, A Guiraud, P-Y Scarabin.   

Abstract

BACKGROUND: Lifetime estrogen exposure has been related to breast cancer risk, osteoporosis, and cardiovascular disease but data on venous thromboembolism (VTE) risk are limited.
METHODS: Data from a hospital-based case-control study among 608 postmenopausal women (191 with a first episode of idiopathic VTE and 417 age-matched controls) were used to determine whether estrogen exposure, as assessed by age at menopause [classified as early (< or = 45 years), normal (46-54 years) and late menopause (> or = 55 years)] and parity, was associated with the risk of VTE.
RESULTS: After adjustment for potential confounding variables, the risk of VTE was increased with each year's delay in the menopause [odds ratio (OR) = 1.06, 95% confidence interval (CI) = 1.02-1.10, P < 0.0075]. When compared with women with normal menopause used as a reference, the adjusted OR for VTE was 0.59 (95% CI = 0.36-0.97) and 2.53 (95% CI = 1.28-4.99) for women with early menopause and late menopause, respectively (P = 0.001). Adjusted OR for VTE was also higher for women with more than two children when compared with those with less than or equal to two children (1.56, 95% CI = 1.03-2.34, P = 0.03). The lowest risk of VTE was observed in women with early menopause and lower parity (adjusted OR = 0.60, 95% CI = 0.30-1.24), the highest risk was among women with late menopause who have had more than two children (adjusted OR = 3.41, 95% CI = 1.46-9.25).
CONCLUSION: These results show that the longer exposure to endogenous estrogen is associated with an increased VTE risk.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16409454     DOI: 10.1111/j.1538-7836.2005.01693.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  11 in total

Review 1.  Impact of sex hormone metabolism on the vascular effects of menopausal hormone therapy in cardiovascular disease.

Authors:  Durr-e-Nayab Masood; Emir C Roach; Katie G Beauregard; Raouf A Khalil
Journal:  Curr Drug Metab       Date:  2010-10       Impact factor: 3.731

2.  Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen.

Authors:  Marianne Canonico; Martine Alhenc-Gelas; Geneviève Plu-Bureau; Valérie Olié; Pierre-Yves Scarabin
Journal:  Menopause       Date:  2010 Nov-Dec       Impact factor: 2.953

3.  Reproductive history, hormone replacement, and incidence of venous thromboembolism: the Longitudinal Investigation of Thromboembolism Etiology.

Authors:  Tetsuya Ohira; Aaron R Folsom; Mary Cushman; Richard H White; Peter J Hannan; Wayne D Rosamond; Susan R Heckbert
Journal:  Br J Haematol       Date:  2010-03-03       Impact factor: 6.998

4.  Predicting Incident Heart Failure in Women With Machine Learning: The Women's Health Initiative Cohort.

Authors:  Geoffrey H Tison; Robert Avram; Gregory Nah; Liviu Klein; Barbara V Howard; Matthew A Allison; Ramon Casanova; Rachael H Blair; Khadijah Breathett; Randi E Foraker; Jeffrey E Olgin; Nisha I Parikh
Journal:  Can J Cardiol       Date:  2021-08-13       Impact factor: 5.223

Review 5.  Vascular actions of estrogens: functional implications.

Authors:  Virginia M Miller; Sue P Duckles
Journal:  Pharmacol Rev       Date:  2008-06-25       Impact factor: 25.468

6.  Prospective study of BMI and the risk of pulmonary embolism in women.

Authors:  Christopher Kabrhel; Raphaëlle Varraso; Samuel Z Goldhaber; Eric B Rimm; Carlos A Camargo
Journal:  Obesity (Silver Spring)       Date:  2009-04-16       Impact factor: 5.002

7.  Age at menopause, reproductive history, and venous thromboembolism risk among postmenopausal women: the Women's Health Initiative Hormone Therapy clinical trials.

Authors:  Marianne Canonico; Geneviève Plu-Bureau; Mary Jo O'Sullivan; Marcia L Stefanick; Barbara Cochrane; Pierre-Yves Scarabin; Joann E Manson
Journal:  Menopause       Date:  2014-03       Impact factor: 2.953

8.  Correlates and consequences of venous thromboembolism: The Iowa Women's Health Study.

Authors:  Pamela L Lutsey; Beth A Virnig; Sara B Durham; Lyn M Steffen; Alan T Hirsch; David R Jacobs; Aaron R Folsom
Journal:  Am J Public Health       Date:  2009-11-12       Impact factor: 9.308

9.  The Risk of Venous Thromboembolism (VTE) in Men with Benign Prostatic Hyperplasia Treated with 5-Alpha Reductase Inhibitors (5ARIs).

Authors:  Olulade Ayodele; Howard J Cabral; David McManus; Susan Jick
Journal:  Clin Epidemiol       Date:  2021-08-03       Impact factor: 4.790

10.  Glucocorticoids and Risk of Venous Thromboembolism in Asthma Patients Aged 20-59 Years in the United Kingdom's CPRD 1995-2015.

Authors:  Olulade A Ayodele; Howard J Cabral; David D McManus; Susan S Jick
Journal:  Clin Epidemiol       Date:  2022-01-20       Impact factor: 4.790

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.